NT-proBNP and Troponin I in Dengue Children

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-04-02

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To discribe concentration of NT-proBNP and Troponin I in Dengue hemorrhagic shock children, in correlation between concentration of NT-proBNP and troponin I with total fluid admission, respiratory support, using inotrope and vasopressor using.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

New Tools for Predicting Capillary Leak Shock During Dengue Fever

NCT04422782

Dengue Fever Children Adults

UNKNOWN NA

Study of Hemodynamics of Neonates by Echocardiography and USCOM

NCT01045252

Sepsis Congenital Heart Disease

UNKNOWN

Functional Hemodynamic Assessment in Shocked Patients in the Pediatric Intensive Care Unit

NCT06720493

Pediatric Shock

NOT_YET_RECRUITING

Predictive Value of Troponin I for Acute Respiratory Distress Syndrome in Children With Shock

NCT02361840

ARDS

UNKNOWN

Volume Responsiveness By Ultrasound Of Carotid Blood Flow In Patients With Cardiogenic Shock

NCT05271227

Cardiogenic Shock Volume Responsiveness Ultrasound

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Treatment of children with Dengue hemorrhagic shock syndrome (DSS) is challenge, especially in cases with hypotensive shock, profound shock or whom do not have a response to initial crystalloid therapy. Currently, treatment of DSS remains almost supportive, with particular emphasis on careful fluid management. However, fluid overload is a common complication of this treatment, lead to many difficulties in management of severe Dengue children, accompany with morbidity and mortality. Diagnosis of fluid overload mostly based on clinical features and chest X-ray or ultrasound. Until now, no biomarker are widely using for diagnosis of fluid overload in clinical. NT-proBNP is secreted when stretching the wall of the cardiac muscle. This may a suitable biomarker to discover the fluid overload state in children with DSS. Troponin I is a biomarker of cardiac muscle damage.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dengue Shock Syndrome Children, Only

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Dengue shock children who admitted to ICU

Exclusion Criteria

* Excluding the cases of children with cardiovascular disease, hyperthyroidism, taking drugs such as insulin, steroid, estrogen, growth hormone, thyroid hormone

Minimum Eligible Age

1 Month

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No